R&D Spending Showdown: Intra-Cellular Therapies, Inc. vs Evotec SE

Intra-Cellular Therapies leads R&D spending over Evotec SE by 180% in 2023.

__timestampEvotec SEIntra-Cellular Therapies, Inc.
Wednesday, January 1, 20141240400021226345
Thursday, January 1, 20151834300087718074
Friday, January 1, 20161810800093831530
Sunday, January 1, 20171761400079419009
Monday, January 1, 201835619000132166913
Tuesday, January 1, 20195843200089124838
Wednesday, January 1, 20206394500065782137
Friday, January 1, 20217220000088845513
Saturday, January 1, 202276642000134715000
Sunday, January 1, 202357519000180142000
Loading chart...

Cracking the code

R&D Spending Trends: A Decade of Innovation

In the competitive landscape of pharmaceutical research, the battle for innovation is often reflected in R&D spending. Over the past decade, Intra-Cellular Therapies, Inc. and Evotec SE have been at the forefront of this financial commitment. From 2014 to 2023, Intra-Cellular Therapies, Inc. consistently outpaced Evotec SE, with an average R&D expenditure nearly double that of its competitor. Notably, in 2023, Intra-Cellular Therapies, Inc. invested approximately 180% more in R&D than Evotec SE, highlighting its aggressive pursuit of groundbreaking therapies.

Key Insights

  • 2018 Surge: Intra-Cellular Therapies, Inc. saw a significant increase in R&D spending, reaching a peak in 2023.
  • Steady Growth: Evotec SE maintained a steady growth trajectory, with a notable increase in 2021.

These trends underscore the strategic priorities of each company, with Intra-Cellular Therapies, Inc. focusing on rapid innovation and Evotec SE on sustainable growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025